Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Denmeade

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Advances in Pharmacology (San Diego, Calif.)|January 1, 1996
Activation of programmed (apoptotic) cell death for the treatment of prostate cancerS R Denmeade, J T Isaacs
BJU International|March 11, 2004
The role of prostate-specific antigen in the clinical evaluation of prostatic diseaseS R Denmeade, J T Isaacs
British Journal of Urology|March 1, 1997
Prostate cancer: where are we and where are we going?S R Denmeade, J T Isaacs
The Prostate|August 29, 2000
In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenograftsS R Khan, S R Denmeade
The Cancer Journal From Scientific American|June 10, 1998
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancerS R Denmeade, J T Isaacs
Cancer Surveys|January 1, 1995
The genetics of programmed (apoptotic) cell deathX Lin, S R Denmeade, J T Isaacs
Cell Calcium|April 7, 1999
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosisB Tombal, S R Denmeade, J T Isaacs
The Prostate|April 1, 1996
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancerS R Denmeade, X S Lin, J T Isaacs
The Prostate|June 22, 2000
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cellsB Tombal, A T Weeraratna, S R Denmeade, et al.
The Prostate|November 20, 1997
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigarginX S Lin, S R Denmeade, L Cisek, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Advances in Pharmacology (San Diego, Calif.)|January 1, 1996
Activation of programmed (apoptotic) cell death for the treatment of prostate cancerS R Denmeade, J T Isaacs
BJU International|March 11, 2004
The role of prostate-specific antigen in the clinical evaluation of prostatic diseaseS R Denmeade, J T Isaacs
British Journal of Urology|March 1, 1997
Prostate cancer: where are we and where are we going?S R Denmeade, J T Isaacs
The Prostate|August 29, 2000
In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenograftsS R Khan, S R Denmeade
The Cancer Journal From Scientific American|June 10, 1998
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancerS R Denmeade, J T Isaacs
Cancer Surveys|January 1, 1995
The genetics of programmed (apoptotic) cell deathX Lin, S R Denmeade, J T Isaacs
Cell Calcium|April 7, 1999
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosisB Tombal, S R Denmeade, J T Isaacs
The Prostate|April 1, 1996
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancerS R Denmeade, X S Lin, J T Isaacs
The Prostate|June 22, 2000
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cellsB Tombal, A T Weeraratna, S R Denmeade, et al.
The Prostate|November 20, 1997
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigarginX S Lin, S R Denmeade, L Cisek, et al.
Pageof 4